The impact of the COVID-19 pandemic on hospitalizations and plasmapheresis therapy in multiple sclerosis and neuromyelitis optica spectrum disorder: a nationwide analysis from Germany
Background: Many countries worldwide reported side effects of the coronavirus disease 2019 (COVID-19) pandemic that have influenced the care of patients with other diseases in both acute and elective settings. Patients with multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) r...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2021-07-01
|
| Series: | Therapeutic Advances in Neurological Disorders |
| Online Access: | https://doi.org/10.1177/17562864211030656 |
| _version_ | 1818865539349479424 |
|---|---|
| author | Daniel Richter Simon Faissner Dirk Bartig Lars Tönges Kerstin Hellwig Ilya Ayzenberg Christos Krogias Ralf Gold |
| author_facet | Daniel Richter Simon Faissner Dirk Bartig Lars Tönges Kerstin Hellwig Ilya Ayzenberg Christos Krogias Ralf Gold |
| author_sort | Daniel Richter |
| collection | DOAJ |
| description | Background: Many countries worldwide reported side effects of the coronavirus disease 2019 (COVID-19) pandemic that have influenced the care of patients with other diseases in both acute and elective settings. Patients with multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) represent the major patient population suffering from an autoimmune inflammatory demyelinating disease of the central nervous system. We aimed to analyze MS and NMOSD hospitalizations, the application of plasmapheresis therapy, and the dynamic during different periods of the COVID-19 pandemic in Germany. Methods: We conducted a nationwide retrospective cross-sectional study using the administrative database of all hospitalized patients with the main diagnosis of MS and NMOSD, including the information on the application of plasmapheresis therapy. We included full-year data from 1463 hospitals of all MS and NMOSD patients hospitalized in 2019 and 2020 in Germany ( n = 87,453). We compared case numbers and plasmapheresis therapy rates of the different pandemic periods in 2020 with the corresponding periods in 2019. Results: We observed a substantial decline of MS and NMOSD patients’ hospitalizations during the different pandemic periods, with the most remarkable decline during the first wave of the pandemic (First diagnosis of MS: −16.8%; relapsing-remitting MS: −34.0%; secondary progressive MS: −48.9%; primary progressive MS: −43.8%; NMOSD: −19.2%). Treatment rates with plasmapheresis increased for MS and NMOSD patients in 2020 compared to 2019 (1.8% versus 1.6%, p = 0.003; 14.0% versus 9.3%, p < 0.001), with a substantial increase during the first wave of the pandemic, especially in NMOSD patients (19.7% versus 8.4%, p < 0.001). Conclusion: There was a marked decline of MS and NMOSD patients’ hospitalizations during the different pandemic periods in 2020, with the most substantial reduction during the pandemic’s first wave and in progressive MS patients. MS and NMOSD patients who needed rescue relapse treatment continued to receive plasmapheresis therapy in Germany. |
| first_indexed | 2024-12-19T10:49:09Z |
| format | Article |
| id | doaj.art-ea1dae9842454400b61397daa8bf34eb |
| institution | Directory Open Access Journal |
| issn | 1756-2864 |
| language | English |
| last_indexed | 2024-12-19T10:49:09Z |
| publishDate | 2021-07-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Neurological Disorders |
| spelling | doaj.art-ea1dae9842454400b61397daa8bf34eb2022-12-21T20:25:07ZengSAGE PublishingTherapeutic Advances in Neurological Disorders1756-28642021-07-011410.1177/17562864211030656The impact of the COVID-19 pandemic on hospitalizations and plasmapheresis therapy in multiple sclerosis and neuromyelitis optica spectrum disorder: a nationwide analysis from GermanyDaniel RichterSimon FaissnerDirk BartigLars TöngesKerstin HellwigIlya AyzenbergChristos KrogiasRalf GoldBackground: Many countries worldwide reported side effects of the coronavirus disease 2019 (COVID-19) pandemic that have influenced the care of patients with other diseases in both acute and elective settings. Patients with multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) represent the major patient population suffering from an autoimmune inflammatory demyelinating disease of the central nervous system. We aimed to analyze MS and NMOSD hospitalizations, the application of plasmapheresis therapy, and the dynamic during different periods of the COVID-19 pandemic in Germany. Methods: We conducted a nationwide retrospective cross-sectional study using the administrative database of all hospitalized patients with the main diagnosis of MS and NMOSD, including the information on the application of plasmapheresis therapy. We included full-year data from 1463 hospitals of all MS and NMOSD patients hospitalized in 2019 and 2020 in Germany ( n = 87,453). We compared case numbers and plasmapheresis therapy rates of the different pandemic periods in 2020 with the corresponding periods in 2019. Results: We observed a substantial decline of MS and NMOSD patients’ hospitalizations during the different pandemic periods, with the most remarkable decline during the first wave of the pandemic (First diagnosis of MS: −16.8%; relapsing-remitting MS: −34.0%; secondary progressive MS: −48.9%; primary progressive MS: −43.8%; NMOSD: −19.2%). Treatment rates with plasmapheresis increased for MS and NMOSD patients in 2020 compared to 2019 (1.8% versus 1.6%, p = 0.003; 14.0% versus 9.3%, p < 0.001), with a substantial increase during the first wave of the pandemic, especially in NMOSD patients (19.7% versus 8.4%, p < 0.001). Conclusion: There was a marked decline of MS and NMOSD patients’ hospitalizations during the different pandemic periods in 2020, with the most substantial reduction during the pandemic’s first wave and in progressive MS patients. MS and NMOSD patients who needed rescue relapse treatment continued to receive plasmapheresis therapy in Germany.https://doi.org/10.1177/17562864211030656 |
| spellingShingle | Daniel Richter Simon Faissner Dirk Bartig Lars Tönges Kerstin Hellwig Ilya Ayzenberg Christos Krogias Ralf Gold The impact of the COVID-19 pandemic on hospitalizations and plasmapheresis therapy in multiple sclerosis and neuromyelitis optica spectrum disorder: a nationwide analysis from Germany Therapeutic Advances in Neurological Disorders |
| title | The impact of the COVID-19 pandemic on hospitalizations and plasmapheresis therapy in multiple sclerosis and neuromyelitis optica spectrum disorder: a nationwide analysis from Germany |
| title_full | The impact of the COVID-19 pandemic on hospitalizations and plasmapheresis therapy in multiple sclerosis and neuromyelitis optica spectrum disorder: a nationwide analysis from Germany |
| title_fullStr | The impact of the COVID-19 pandemic on hospitalizations and plasmapheresis therapy in multiple sclerosis and neuromyelitis optica spectrum disorder: a nationwide analysis from Germany |
| title_full_unstemmed | The impact of the COVID-19 pandemic on hospitalizations and plasmapheresis therapy in multiple sclerosis and neuromyelitis optica spectrum disorder: a nationwide analysis from Germany |
| title_short | The impact of the COVID-19 pandemic on hospitalizations and plasmapheresis therapy in multiple sclerosis and neuromyelitis optica spectrum disorder: a nationwide analysis from Germany |
| title_sort | impact of the covid 19 pandemic on hospitalizations and plasmapheresis therapy in multiple sclerosis and neuromyelitis optica spectrum disorder a nationwide analysis from germany |
| url | https://doi.org/10.1177/17562864211030656 |
| work_keys_str_mv | AT danielrichter theimpactofthecovid19pandemiconhospitalizationsandplasmapheresistherapyinmultiplesclerosisandneuromyelitisopticaspectrumdisorderanationwideanalysisfromgermany AT simonfaissner theimpactofthecovid19pandemiconhospitalizationsandplasmapheresistherapyinmultiplesclerosisandneuromyelitisopticaspectrumdisorderanationwideanalysisfromgermany AT dirkbartig theimpactofthecovid19pandemiconhospitalizationsandplasmapheresistherapyinmultiplesclerosisandneuromyelitisopticaspectrumdisorderanationwideanalysisfromgermany AT larstonges theimpactofthecovid19pandemiconhospitalizationsandplasmapheresistherapyinmultiplesclerosisandneuromyelitisopticaspectrumdisorderanationwideanalysisfromgermany AT kerstinhellwig theimpactofthecovid19pandemiconhospitalizationsandplasmapheresistherapyinmultiplesclerosisandneuromyelitisopticaspectrumdisorderanationwideanalysisfromgermany AT ilyaayzenberg theimpactofthecovid19pandemiconhospitalizationsandplasmapheresistherapyinmultiplesclerosisandneuromyelitisopticaspectrumdisorderanationwideanalysisfromgermany AT christoskrogias theimpactofthecovid19pandemiconhospitalizationsandplasmapheresistherapyinmultiplesclerosisandneuromyelitisopticaspectrumdisorderanationwideanalysisfromgermany AT ralfgold theimpactofthecovid19pandemiconhospitalizationsandplasmapheresistherapyinmultiplesclerosisandneuromyelitisopticaspectrumdisorderanationwideanalysisfromgermany AT danielrichter impactofthecovid19pandemiconhospitalizationsandplasmapheresistherapyinmultiplesclerosisandneuromyelitisopticaspectrumdisorderanationwideanalysisfromgermany AT simonfaissner impactofthecovid19pandemiconhospitalizationsandplasmapheresistherapyinmultiplesclerosisandneuromyelitisopticaspectrumdisorderanationwideanalysisfromgermany AT dirkbartig impactofthecovid19pandemiconhospitalizationsandplasmapheresistherapyinmultiplesclerosisandneuromyelitisopticaspectrumdisorderanationwideanalysisfromgermany AT larstonges impactofthecovid19pandemiconhospitalizationsandplasmapheresistherapyinmultiplesclerosisandneuromyelitisopticaspectrumdisorderanationwideanalysisfromgermany AT kerstinhellwig impactofthecovid19pandemiconhospitalizationsandplasmapheresistherapyinmultiplesclerosisandneuromyelitisopticaspectrumdisorderanationwideanalysisfromgermany AT ilyaayzenberg impactofthecovid19pandemiconhospitalizationsandplasmapheresistherapyinmultiplesclerosisandneuromyelitisopticaspectrumdisorderanationwideanalysisfromgermany AT christoskrogias impactofthecovid19pandemiconhospitalizationsandplasmapheresistherapyinmultiplesclerosisandneuromyelitisopticaspectrumdisorderanationwideanalysisfromgermany AT ralfgold impactofthecovid19pandemiconhospitalizationsandplasmapheresistherapyinmultiplesclerosisandneuromyelitisopticaspectrumdisorderanationwideanalysisfromgermany |